AmerisourceBergen Corp. (NYSE:ABC) has been given an average rating of “Buy” by the twenty-one ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $103.34.
A number of equities analysts have recently issued reports on the company. Mizuho set a $100.00 price target on AmerisourceBergen and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Needham & Company LLC upped their price target on AmerisourceBergen from $86.00 to $88.00 and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Zacks Investment Research raised AmerisourceBergen from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a research report on Thursday, February 8th. Cowen reaffirmed a “buy” rating and set a $108.00 price target on shares of AmerisourceBergen in a research report on Tuesday, February 27th. Finally, Leerink Swann set a $105.00 price target on AmerisourceBergen and gave the stock a “buy” rating in a research report on Tuesday, January 2nd.
AmerisourceBergen (NYSE ABC) traded down $0.23 during trading on Friday, reaching $97.13. The company’s stock had a trading volume of 454,961 shares, compared to its average volume of 2,048,128. The company has a debt-to-equity ratio of 1.61, a quick ratio of 0.50 and a current ratio of 0.95. The stock has a market capitalization of $21,654.97, a price-to-earnings ratio of 20.96, a P/E/G ratio of 1.47 and a beta of 1.03. AmerisourceBergen has a one year low of $71.90 and a one year high of $106.27.
AmerisourceBergen (NYSE:ABC) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.20. The business had revenue of $40.47 billion for the quarter, compared to the consensus estimate of $40.42 billion. AmerisourceBergen had a return on equity of 53.65% and a net margin of 0.66%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.36 earnings per share. research analysts anticipate that AmerisourceBergen will post 6.58 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Monday, March 5th. Investors of record on Tuesday, February 20th were given a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 1.56%. The ex-dividend date was Friday, February 16th. AmerisourceBergen’s payout ratio is 32.76%.
In related news, insider Dale Danilewitz sold 3,121 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $92.12, for a total value of $287,506.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard W. Gochnauer sold 2,278 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $101.13, for a total value of $230,374.14. Following the sale, the director now directly owns 13,225 shares in the company, valued at $1,337,444.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 156,809 shares of company stock worth $14,988,589. 27.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Hikari Tsushin Inc. acquired a new stake in AmerisourceBergen during the 4th quarter worth about $106,000. Delpha Capital Management LLC acquired a new stake in AmerisourceBergen during the 4th quarter worth about $137,000. Vantage Investment Advisors LLC acquired a new stake in AmerisourceBergen during the 4th quarter worth about $156,000. TRUE Private Wealth Advisors acquired a new stake in AmerisourceBergen during the 4th quarter worth about $203,000. Finally, Zeke Capital Advisors LLC acquired a new stake in AmerisourceBergen during the 3rd quarter worth about $210,000. 67.33% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/brokerages-set-amerisourcebergen-corp-abc-target-price-at-103-34.html.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.